Effect of naringin on bone cells

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Statins, HMG-CoA reductase inhibitors, enhance bone formation by increasing BMP-2 gene expression.
• The mevalonate pathway in cholesterol production is a target for HMG-CoA reductase inhibitors.
• Naringin, a flavonoid found in citrus fruits, also inhibits HMG-CoA reductase.

Purpose of the Study:

• To investigate the in vitro effects of naringin on osteoblastic cell activities.
• To determine if naringin, as an HMG-CoA reductase inhibitor, influences bone cell function.
• To compare naringin's effects with known bone-promoting agents like statins.

Main Methods:

• UMR 106 osteoblastic cell line was used for in vitro experiments.
• Cells were treated with varying concentrations of naringin (0.001–0.1 µmol/L) for 24, 48, and 72 hours.
• Cellular activities were assessed using MTT assay, total protein content assay, and alkaline phosphatase activity assays.

Main Results:

• Naringin treatment dose-dependently increased cell proliferation, as indicated by MTT assay results (60–80% increase at 0.1 µmol/L).
• Total protein content also increased with naringin exposure in a dose-dependent manner (9–20% increase at 0.1 µmol/L).
• Alkaline phosphatase activity was significantly elevated by naringin, with a notable increase of up to 20% at the highest concentration (0.1 µmol/L).

Conclusions:

• Naringin significantly enhances osteoblastic cell activities in vitro.
• This study is the first to specifically examine naringin's impact on bone cell functions.
• Inhibition of HMG-CoA reductase by naringin offers a potential mechanism for increasing bone cell activity, similar to statins.